What does this research mean for the field?

Inhaled treprostinil reduces the decline in FVC and the occurrence of clinical worsening events in patients with idiopathic pulmonary fibrosis compared to placebo over 52 weeks. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim is to evaluate the efficacy of inhaled treprostinil for improving lung function in patients with idiopathic pulmonary fibrosis (IPF).

March 14, 2026

Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis

Puntos clave

The aim is to evaluate the efficacy of inhaled treprostinil for improving lung function in patients with idiopathic pulmonary fibrosis (IPF).
Conducted a 52-week clinical trial comparing inhaled treprostinil with placebo.
Measured forced vital capacity (FVC) as a primary outcome.
Documented clinical worsening events.
Inhaled treprostinil resulted in a smaller decline in FVC compared to placebo.
Fewer clinical worsening events were observed in the treprostinil group than in the placebo group.

Resumen

In patients with IPF, inhaled treprostinil was associated with a smaller decline in FVC and fewer clinical-worsening events than placebo over a period of 52 weeks. (Funded by United Therapeutics; TETON-2 ClinicalTrials.gov number, NCT05255991.).

Me gusta

Guardar

Cite This Study

Nathan et al. (Wed,) studied this question.

synapsesocial.com/papers/69b4fc0eb39f7826a300cb06 https://doi.org/https://doi.org/10.1056/nejmoa2512911

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Me gusta

Guardar